Alpha Tau Medical's combination therapy abstract has been selected for podium presentation at the AHNS International Conference on Head and Neck Cancer in July.

The Toronto-based AI Alzheimer's screening company plans to list on the TSX Venture Exchange in May, raising up to C$4 million at

Amazon's integrated GLP-1 programme combines One Medical clinical care, Amazon Pharmacy, and same-day delivery, but cash-pay and new patients face notable

AMG Critical Materials posted $44m adjusted EBITDA in Q1 2026, ahead of guidance, driven by vanadium gains and the AURA acquisition.

The Bedford-based orthopaedic biotech grew Q1 2026 revenue to $29.6m and lifted gross margin eight points to 64%, driven by its Integrity regenerative

The physician-led practice manager has abolished over $1.5bn in patient debt via Cascade365 and non-profit Undue Medical Debt, targeting low-income patients.

The Cambridge DDR biotech has appointed a Chief Business Officer, General Counsel, and VP of Regulatory Affairs ahead of a potential US commercialisation push.

Avacta's Science Day 2026 showcased tumour-selectivity and dual-payload data positioning its PDC platform ahead of approved ADCs.

Abdakibart met HiSCR75 at both doses in the 253-patient LOTUS trial, with Avalo now planning a registrational Phase 3 programme in hidradenitis suppurativa.

Avalyn will show poster data on inhaled pirfenidone nebuliser usability and patient-centred supportive care in pulmonary fibrosis at ATS in Orlando.

BEYONTTRA becomes the first near-complete TTR stabiliser approved in Brazil, backed by Phase 3 data showing a 42% cut in cardiovascular mortality and hospitalisation.

The Durham-based medical-technology company reported Q1 net sales of $132.1m and lifted its full-year adjusted EPS and cash-flow forecasts.